2017
DOI: 10.1016/j.surge.2016.05.002
|View full text |Cite
|
Sign up to set email alerts
|

Pancreatic cancer actionable genes in precision medicine and personalized surgery

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with an overall 5-year survival rate less than 5% due to the poor early diagnosis and lack of effective therapeutic options. The most effective therapy remains surgery, however post-operative survival could be enhanced with effective adjuvant therapy. The massive information gained from Omics techniques on PDAC at the beginning of the 21st century is a remarkable accomplishment. However, the information gained from the omics data, including next genera… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
5
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 53 publications
0
5
0
Order By: Relevance
“…Molecularly targeted cancer drugs are often developed with molecular diagnostics that attempt to identify which patients will achieve better outcomes on the new drug, and thus avoid innate treatment resistance. Such predictive biomarkers are playing an increasingly important role in precision oncology [10], but it is also recognized that the complexity of one patient's tumor cannot be sufficiently impacted by the use of a single marker/single-agent method.…”
Section: Discussionmentioning
confidence: 99%
“…Molecularly targeted cancer drugs are often developed with molecular diagnostics that attempt to identify which patients will achieve better outcomes on the new drug, and thus avoid innate treatment resistance. Such predictive biomarkers are playing an increasingly important role in precision oncology [10], but it is also recognized that the complexity of one patient's tumor cannot be sufficiently impacted by the use of a single marker/single-agent method.…”
Section: Discussionmentioning
confidence: 99%
“…Previously, the term "personalized surgery" was used exclusively to describe of the cancer treatment based on genetics data from patient [21] or the customized surgical treatment based on variant anatomy features [22]. Using a combination of coding (DNA, RNA) and signal (proteins and nucleic acids) molecules to regulate the body's functional for editing the genome and changing the cellular organization allows us to consider the possibility of personalizing surgical interventions based on the "omics" data of the patient's body (genome, epigenome, transcriptome, proteome, metabolome) to achieve an individual physiological response.…”
Section: Personalized Surgerymentioning
confidence: 99%
“…Previously, the term "personalized surgery" was used exclusively to describe of the cancer treatment based on genetics data from patient [21] or the customized surgical treatment based on variant anatomy features [22]. Clinical trials and training of "surgical team 2.0" will differ from the corresponding procedures when using of existing drugs and medical products.…”
Section: Personalized Surgerymentioning
confidence: 99%